Program

PO3-9-19

MENINGOCOCCAL OMV. A PLATFORM FOR VACCINE DEVELOPMENT

[Speaker] Reinaldo Acevedo:1
[Co-author] Caridad Zayas:1, Elizabeth Gonzalez:1, Mabel Hernandez:1, Claudia Acosta:1, Yisabel Aranguren:1, Dagmar Garcia:1
1:Biologic Evaluation Department, Finlay Vaccine Institute, Cuba

Outer membrane Vesicles (OMV) derived from Neisseria meningitidis serogroup B have been used for more than 30 years in the formulation of meningococcal vaccines against this serogroup. Additionally, the immuneadjuvant effect of OMV was demonstrated in related as well as coformulated non meningococcus antigens, like proteins, peptides, polysaccharides or small hapten molecules. The aim of this work is to present some evidences obtained from the vaccine and adjuvant evaluation of the OMV derived from the Cu385 Cuban epidemic strain. The OMV were evaluated in the context of different antigenic materials, different immunization routes and schedules. Formulation of OMV with meningococcal serogroup C plain polysaccharide (VAMENGOC BC) improve the immune response induced against the polysaccharide but also have an adjuvant effect on conjugated polysaccharides that are admixed with the OMV. The formulation of OMV via combination, incorporation or conjugation, with recombinant or purified antigens, like Ovalbumin or the gD2 protein of herpes virus type II, or small hapten molecules like nicotine, induce high immune response with protective potential. Overall, this work shows that the adjuvant effect of OMV is based on the immunestimulant effect of bacterial components in the vesicles, like LPS, and the efficient delivery of the antigenic and stimulator molecules. OMV have shown to be capable to become in a useful vaccine platform for development of new prophylactics or therapeutic vaccines
Advanced Search